The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...

Lonza, a global leader in the pharmaceutical, biotech, and nutraceutical markets, has announced a significant expansion of its clinical manufacturing services at its small molecules site in Bend, ...

In an in-depth conversation, OSP senior editor, Liza Laws, interviews Adrian Kizewski, associate director at IQVIA, to uncover the transformative impact of the Sub-population Optimization & Modeling ...

She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...